For Immediate Release

Chicago, IL - May 8, 2009 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Auxilium Pharmaceuticals, Inc. (AUXL), Pfizer (PFE), Cognizant Technology Solutions Corp. (CTSH), Neurocrine Biosciences, Inc. (NBIX) and Coca-Cola FEMSA S.A. de C.V. (KOF).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=4579.

Here are highlights from Thursday's Analyst Blog:

Auxilium a Buy at $20

Auxilium Pharmaceuticals, Inc. (AUXL) reported financial results for the first quarter 2009 on May 6, 2009. Total revenues for the first quarter were $34.7 million, an increase of 28% over the first quarter

...

Auxilium Pharmaceuticals, Inc. (AUXL) reported financial results for the first quarter 2009 on May 6, 2009. Total revenues for the first quarter were $34.7 million, an increase of 28% over the first quarter in 2008.Revenues consisted of approximately $32.5 million in U.S. sales of Testim, up 20% year-over-year, $1.3 million in milestone recognition from Ferring International S.A. on ex-U.S. Testim activities, and $0.9 million in amortization from the previous upfront payment from Pfizer (PFE). This was slightly lower than expected by about $2.0 million based on lower sales of Testim.Management noted that managed-care changes and inventory de-stocking negatively impacted sales. Also, the difficult economic environment had a negative impact on Testim sales during the first quarter. Net loss for the first quarter totaled $13.2 million, or $0.31 per share. This was a slightly greater loss than expected based on lower sales of Testim ...